Just M, Berger R, Glück R, Wegmann A
Schweiz Med Wochenschr. 1985 Nov 30;115(48):1727-30.
The results of a field trial with a novel, live attenuated human diploid cell vaccine (HDCV) against measles, mumps and rubella are described. The study was performed double blind and included 120 children aged 15 to 24 months. 60 children received the new vaccine and a control group of another 60 children were vaccinated with M-M-RR II. The seroconversion rates found 6 to 8 weeks after the vaccination were high without exception (95% to 100%). The multiple chi 2-test revealed no statistically significant difference in immunogenic efficacy between the two vaccines (p greater than 0.05). No reports of side effects were received from the 12 physicians participating in the study. It is pointed out that all components of the new vaccine are highly attenuated and that the vaccine is free of avian protein, animal protein extracts and antibiotics. This excludes all theoretical and practical contraindications due to the corresponding hypersensitivities.
描述了一种新型减毒活人类二倍体细胞疫苗（HDCV）针对麻疹、腮腺炎和风疹的现场试验结果。该研究采用双盲进行，纳入了120名15至24个月大的儿童。60名儿童接种了新疫苗，另一组60名儿童作为对照组接种了麻腮风疫苗II（M-M-RR II）。接种疫苗6至8周后的血清转化率无一例外都很高（95%至100%）。多重卡方检验显示两种疫苗在免疫原性效力上无统计学显著差异（p大于0.05）。参与研究的12名医生均未收到副作用报告。指出新疫苗的所有成分均高度减毒，且该疫苗不含禽蛋白、动物蛋白提取物和抗生素。这排除了因相应超敏反应导致的所有理论和实际禁忌证。
